Ali Keshavarz-Shokri

This inventor holds 33 USPTO granted patents and 18 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Vertex Pharmaceuticals, Inc., Biomed Valley Discoveries, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ali Keshavarz-Shokri. Retrieved from https://idiyas.com/inventor/ali-keshavarz-shokri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 17)

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 994(Granted Patents)

Company Filing History:

33 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

5 out of 43

Biomed Valley Discoveries, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

Pharmaceutical Compositions

Sodium Channels

Prodrugs

Modulators

Crystalline Forms

Solid Forms

Cyclopropanecarboxamide

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12384762 - Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2025-08-12),

2. 12187698 - Crystalline forms of CHClNO (2025-01-07),

3. 12065432 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid (2024-08-20),

4. 11773119 - Prodrugs of pyridone amides useful as modulators of sodium channels (2023-10-03),

5. 11578062 - Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (2023-02-14),

6. 11453655 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-09-27),

7. 11390600 - Crystalline forms of CHClNO (2022-07-19),

8. 11186566 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2021-11-30),

9. 10906891 - Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (2021-02-02),

10. 10793547 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-10-06),

11. 10787472 - Prodrugs of pyridone amides useful as modulators of sodium channels (2020-09-29),

12. 10738027 - Crystalline forms of CHClNO (2020-08-11),

13. 10597384 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid (2020-03-24),

14. 10570115 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-02-25),

15. 10253054 - Prodrugs of pyridone amides useful as modulators of sodium channels (2019-04-09),

Title: The Innovative Ventures of Ali Keshavarz-Shokri

Introduction:

Ali Keshavarz-Shokri, a brilliant inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 30 patents. His latest patents showcase his pioneering work in developing prodrugs of pyridone amides for the modulation of sodium channels and solid forms of certain medicinal compounds.

Latest Patents:

One of Ali Keshavarz-Shokri's recent patents involves prodrug compounds with advantageous solubility and physicochemical properties. These compounds, as per the invention, are crucial in treating various disorders, particularly pain. Moreover, his invention of solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide holds promise in pharmaceutical formulations and treatments.

Career Highlights:

Ali Keshavarz-Shokri has showcased his exceptional skills in companies like Vertex Pharmaceuticals, Inc., and Biomed Valley Discoveries, Inc.. His tenure in these renowned organizations has been marked by groundbreaking innovations and advancements in the pharmaceutical industry.

Collaborations:

Throughout his career, Ali Keshavarz-Shokri has collaborated with esteemed professionals such as Beili Zhang and Mariusz Krawiec. These collaborations have played a pivotal role in shaping his innovative journey and fostering a culture of excellence in his work.

Conclusion:

In conclusion, Ali Keshavarz-Shokri's relentless dedication to innovation and his trailblazing inventions in the realm of pharmaceuticals have not only established him as a respected inventor but have also significantly contributed to the advancement of medical science. His visionary approach and prolific contributions continue to inspire and drive progress in the field of healthcare and pharmaceuticals.

Profile summary based on public USPTO records.